Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a 
unique, patented platform for the development of diagnostic tests, announced 
today that Australia has been added to the list of countries that have 
authorized the Logix Smart(TM) COVID-19 for use in detecting SARS-CoV-2, the 
virus that causes COVID-19.

Logo - https://mma.prnewswire.com/media/1141654/Co_Diagnostics_Official_Logo.jpg

Australia joins the United States, India, Mexico, the European Community and 
others as a region where the Company's test can be sold and used as a 
coronavirus in vitro diagnostic (IVD). The Australian Government Register of 
Therapeutic Goods ( 
https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=E28E8266A66468E7CA2585B90042BA51&agid=PrintDetailsPublic&actionid=1

 ) Certificate was recently issued to the Company's distributor in Australia, 
approving the distributor to supply the Class 3 IVD to the Australian market.

Dwight Egan, CEO of Co-Diagnostics, commented, "Co-Diagnostics recognizes the 
importance of accurate, high-throughput testing in combating surges of 
coronavirus infections, and we are gratified that our test is being used to 
help people in so many countries to safely navigate this ongoing pandemic, now 
also including Australia."

The news follows recent reports ( 
https://c212.net/c/link/?t=0&l=en&o=2879460-1&h=2244289416&u=https%3A%2F%2Fwww.cnn.com%2F2020%2F08%2F02%2Faustralia%2Fvictoria-coronavirus-state-of-disaster-intl%2Findex.html&a=recent+reports 
) of a soaring coronavirus outbreak in Melbourne, prompting the state of 
Victoria to declare a "state of disaster" and to strengthen lockdown measures.

The CE-marked and FDA EUA Co-Diagnostics Logix Smart COVID-19 test ( 
https://c212.net/c/link/?t=0&l=en&o=2879460-1&h=2898305481&u=http%3A%2F%2Fcodiagnostics.com%2Fproducts%2Fdiagnostic-solutions%2Flogix-smart-covid19%2F&a=Logix+Smart+COVID-19+test 
) is currently available to all clinical laboratories certified under Clinical 
Laboratory Improvement Amendments (CLIA), and is authorized to be used for the 
diagnosis of SARS-CoV-2, the virus that causes COVID-19, in the US and many 
other countries.
 
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company 
that develops, manufactures and markets a new, state-of-the-art diagnostics 
technology. The Company's technology is utilized for tests that are designed 
using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The 
Company also uses its proprietary technology to design specific tests to locate 
genetic markers for use in industries other than infectious disease and license 
the use of those tests to specific customers.

Forward-Looking Statements:
This press release contains forward-looking statements. Forward-looking 
statements can be identified by words such as "believes," "expects," 
"estimates," "intends," "may," "plans," "will" and similar expressions, or the 
negative of these words. Such forward-looking statements are based on facts and 
conditions as they exist at the time such statements are made and predictions 
as to future facts and conditions. Forward-looking statements in this release 
include statements regarding the (i) use of funding proceeds, (ii) expansion of 
product distribution, (iii) acceleration of initiatives in liquid biopsy and 
SNP detection, (iv) use of the Company's liquid biopsy tests by laboratories, 
(v) capital resources and runway needed to advance the Company's products and 
markets, (vi) increased sales in the near-term, (vii) flexibility in managing 
the Company's balance sheet, (viii) anticipation of business expansion, and 
(ix) benefits in research and worldwide accessibility of the CoPrimer 
technology and its cost-saving and scientific advantages. Forward-looking 
statements are subject to inherent uncertainties, risks and changes in 
circumstances. Actual results may differ materially from those contemplated or 
anticipated by such forward-looking statements. Readers of this press release 
are cautioned not to place undue reliance on any forward-looking statements. 
The Company does not undertake any obligation to update any forward-looking 
statement relating to matters discussed in this press release, except as may be 
required by applicable securities laws. 

Company Contact:
Andrew Benson
Head of Investor Relations
+1 801-438-1036
investors@codiagnostics.com


Media Contact:
Jennifer Webb
Coltrin & Associates, Inc
+1.267.912.1173
jennifer_webb@coltrin.com

Source: Co-Diagnostics